Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1535-1542

  McCullumsmith, Robert E ^a   Hammond, John ^a   Funk, Adam ^a   Meador Woodruff, James H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

AMPA; D serine; Glutamate; Glycine; Kainate; Lamotrigene; NMDA; Schizophrenia

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; ACAMPROSATE; AMPA RECEPTOR; AMPAKINE; ANIRACETAM; CHLORPROMAZINE; CLOZAPINE; CYCLOSERINE; DEXTRO ALANINE; DEXTRO SERINE; GLUTAMIC ACID; GLYCINE; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; LAMOTRIGINE; MEMANTINE; MILACEMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PLACEBO; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALCOHOLISM; ALZHEIMER DISEASE; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGATIVE SYNDROME; NEUROMODULATION; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; SCHIZOPHRENIA; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; GLUTAMIC ACID; HUMANS; RECEPTORS, IONOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 84862623077     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784899     Document Type: Article

References (142)

1. Buchanan, R.W.; Carpenter, W.T. Schizophrenia: Introduction and Overview. In: Comprehensive Textbook of Psychiatry. Sadock, B.J., Sadock, V.A., Eds.; Lippincott, Williams, and Wilkins: Philadelphia, 2000, pp. 1096-1110.
2. Healy, D. The Creation of Psychopharmacology. Harvard University Press: Cambridge, MA, 2002.
3. Swazey, J. Chlorpromazine in Psychiatry. MIT Press: Cambridge, MA, 1974.
4. Shorter, E. A History of Psychiatry: From the era of the asylum to the age of Prozac. 2nd ed. John Wiley and Sons: Hoboken, NJ, 1998.
5. Wilson, J.M.; Sanyal, S.; Van Tol, H.H. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action. Eur. J. Pharmacol., 1998, 351(3), 273-286.
6. Hyttel, J.; Larsen J.J.; Christensen A.V.; Arnt J. Receptor-bindingprofiles of neuroleptics. Psychopharmacol. Suppl., 1985, 2, 9-18.
7. Meltzer, H.Y.; Li, Z.; Kaneda, Y.; Ichikawa, J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27(7), 1159-1172.
8. Hubl, D.; Koenig, T.; Strik, W.; Federspiel, A.; Kreis, R.; Boesch, C.; Maier, S.E.; Schroth, G.; Lovblad, K.; Dierks, T. Pathways that make voices: white matter changes in auditory hallucinations. Arch. Gen. Psychiatry, 2004, 61(7), 658-668.
9. Luchins, D.J. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications? Adm. Policy Ment. Health, 2006, 33(5), 541-543.
10. Basil, B.; Mathews, M.; Adetunji, B.; Budur, K. The CATIE study. Am. J. Psychiatry, 2006, 163(3), 555; 555-556.
11. Luchins, D.J., Interpreting the results of the CATIE study. Psychiatr. Serv., 2006, 57(1), 139-140.
12. Lieberman, J.A.; Hsiao, J.K. Interpreting the results of the CATIE study. Psychiatr. Serv., 2006, 57(1), 139.
13. Brenner, H.D.; Dencker, S.J.; Goldstein, M.J.; Hubbard, J.W.; Keegan, D.L.; Kruger, G.; Kulhanek, F.; Liberman, R.P.; Malm, U.; Midha, K.K. Defining treatment refractoriness in schizophrenia. Schizophr. Bull., 1990, 16(4), 551-561.
14. Harrow, M.; Sands, J.R.; Silverstein, M.L.; Goldberg, J.F. Course and outcome for schizophrenia versus other psychotic patients: a longitudinal study. Schizophr. Bull., 1997, 23(2), 287-303.
15. Hamdani, N.; Tabeze, J.P.; Ramoz, N.; Ades, J.; Hamon, M.; Sarfati, Y.; Boni, C.; Gorwood, P. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur. Neuropsychopharmacol., 2008, 18(1), 34-40.
16. Malhotra, A.K.; Burdick, K.E.; Razi, K.; Bates, J.A.; Sanders, M.; Kane, J.M. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity? Schizophr. Res., 2006, 87(1/3), 181-184.
17. Joober, R.; Benkelfat, C.; Toulouse, A.; Lafrenière, R.G.; Lal, S.; Ajroud, S.; Turecki, G.; Bloom, D.; Labelle, A.; Lalonde, P.; Alda, M.; Morgan, K.; Palmour, R.; Rouleau, G.A. Analysis of 14 CAG repeat-containing genes in schizophrenia. Am. J. Med. Genet., 1999, 88(6), 694-699.
18. Potkin, S.G.; Bera, R.; Gulasekaram, B.; Costa, J.; Hayes, S.; Jin, Y.; Richmond, G.; Carreon, D.; Sitanggan, K.; Gerber, B. Plasma clozapine concentrations predict clinical response in treatmentresistant schizophrenia. J. Clin. Psychiatry, 1994, 55(Suppl. B), 133-136.
19. Harvey, P.D.; Putnam, K.M.; Davidson, M.; Kahn, R.S.; Powchik, P.; McQueeney, R.; Keefe, R.S.; Davis, K.L. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res., 1991, 38(3), 285-292.
20. Lieberman, J.A.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; Severe, J.; Hsiao, J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 2005, 353(12), 1209-1223.
21. Meltzer, H.Y.; Stahl, S.M. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull., 1976, 2(1), 19-76.
22. Reynolds, G.P. Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. Br. J. Psychiatry, 1989, 155, 305-316.
23. Seeman, P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1987, 1(2), 133-152.
24. Ellison, G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res. Brain Res. Rev., 1994, 19(2), 223-239.
25. Laruelle, M.; Abi-Dargham, A.; Gil, R.; Kegeles, L.; Innis, R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry, 1999, 46(1), 56-72.
26. Joyce, J.N.; Meador-Woodruff, J.H. Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia. Neuropsychopharmacology, 1997, 16(6), 375-384.
27. Goff, D.C.; Wine, L. Glutamate in schizophrenia: clinical and research implications. Schizophr. Res., 1997, 27(2/3), 157-168.
28. Coyle, J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry, 1996, 3(5), 241-253.
29. Javitt, D.C.; Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry, 1991, 148(10), 1301-1308.
30. Tamminga, C. Glutamatergic aspects of schizophrenia. Br. J. Psychiatry Suppl., 1999, (37), 12-15.
31. Krystal, J.H.; Karper, L.P.; Seibyl, J.P.; Freeman, G.K.; Delaney, R.; Bremner, J.D.; Heninger, G.R.; Bowers, M.B. Jr.; Charney, D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry, 1994, 51(3), 199-214.
32. Bjerkenstedt, L.; Edman, G.; Hagenfeldt, L.; Sedvall, G.; Wiesel, F.A. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br. J. Psychiatry, 1985, 147, 276-282.
33. Macciardi, F.; Lucca, A.; Catalano, M.; Marino, C.; Zanardi, R.; Smeraldi, E. Amino acid patterns in schizophrenia: some new findings. Psychiatry Res., 1990, 32(1), 63-70.
34. Gattaz, W.F.; Gasser, T.; Beckmann, H. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol. Psychiatry, 1985, 20(4), 360-366.
35. Perry, T.L. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci. Lett., 1982, 28(1), 81-85.
36. Korpi, E.R.; Kaufmann, C.A.; Marnela, K.M.; Weinberger, D.R. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res., 1987, 20(4), 337-345.
37. Alfredsson, G.; Wiesel, F.A. Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology (Berl.), 1989, 99(3), 322-327.
38. Deutsch, S.I.; Mastropaolo, J.; Schwartz, B.L.; Rosse, R.B.; Morihisa, J.M. A glutamatergic hypothesis of schizophrenia. Rationale for pharmacotherapy with glycine. Clin. Neuropharmacol., 1989, 12(1), 1-13.
39. Omori, M.; Pearce, J.; Komoroski, R.A.; Griffin, W.S.; Mrak, R.E.; Husain, M.M.; Karson, C.N. In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biol. Psychiatry, 1997, 42(5), 359-366.
40. Kegeles, L.S.; Humaran, T.J.; Mann, J.J. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol. Psychiatry, 1998, 44(6), 382-398.
41. Deicken, R.F.; Zhou, L.; Corwin, F.; Vinogradov, S.; Weiner, M.W. Decreased left frontal lobe N-acetylaspartate in schizophrenia. Am. J. Psychiatry, 1997, 154(5), 688-690.
42. Steel, R.M.; Bastin, M.E.; McConnell, S.; Marshall, I.; Cunningham-Owens, D.G.; Lawrie, S.M.; Johnstone, E.C.; Best, J.J. Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls. Psychiatry Res., 2001, 106(3), 161-170.
43. Choe, B.Y.; Kim, K.T.; Suh, T.S.; Lee, C.; Paik, I.H.; Bahk, Y.W.; Shinn, K.S.; Lenkinski, R.E. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad. Radiol., 1994, 1(3), 211-216.
44. Bertolino, A.; Callicott, J.H.; Elman, I.; Mattay, V.S.; Tedeschi, G.; Frank, J.A.; Breier, A.; Weinberger, D.R. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol. Psychiatry, 1998, 43(9), 641-648.
45. Bertolino, A.; Callicott, J.H.; Nawroz, S.; Mattay, V.S.; Duyn, J.H.; Tedeschi, G.; Frank, J.A.; Weinberger, D.R. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology, 1998, 18(1), 1-9.
46. Cecil, K.M.; Lenkinski, R.E.; Gur, R.E.; Gur, R.C. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology, 1999, 20(2), 131-140.
47. Callicott, J.H.; Bertolino, A.; Egan, M.F.; Mattay, V.S.; Langheim, F.J.; Weinberger, D.R. Selective relationship between prefrontal Nacetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry, 2000, 157(10), 1646-1651.
48. Ghose, S.; Weickert, C.S.; Colvin, S.M.; Coyle, J.T.; Herman, M.M.; Hyde, T.M.; Kleinman, J.E. Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology, 2004, 29(1), 117-125.
49. Burbaeva, G.; Boksha, I.S.; Turishcheva, M.S.; Vorobyeva, E.A.; Savushkina, O.K.; Tereshkina EB. Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27(4), 675-680.
50. Ghose, S.; Chin, R.; Gallegos, A.; Roberts, R.; Coyle, J.; Tamminga, C. Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia. Schizophr. Res., 2009, 111(1/3), 131-137.
51. Passani, L.A.; Vonsattel, J.P.; Carter, R.E.; Coyle, J.T. Nacetylaspartylglutamate, N-acetylaspartate, and N-acetylated alphalinked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol. Chem. Neuropathol., 1997, 31(2), 97-118.
52. Tsai, G.; Passani LA; Slusher, B.S.; Carter, R.; Baer, L.; Kleinman, J.E.; Coyle, J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry, 1995, 52(10), 829-836.
53. Lahti, A.C.; Holcomb, H.H.; Medoff, D.R.; Tamminga, C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport., 1995, 6(6), 869-872.
54. rd edition). Javitt, D., Eds; Springer Publishers, New York: 2008.
55. Clinton, S.M.; Meador-Woodruff, J.H. Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophr. Res., 2004, 69(2/3), 237-253.
56. Meador-Woodruff, J.H.; Clinton, S.M.; Beneyto, M.; McCullumsmith, R.E. Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Ann. N. Y. Acad. Sci., 2003, 1003, 75-93.
57. Meador-Woodruff, J.H.; Healy, D.J. Glutamate receptor expression in schizophrenic brain. Brain Res. Brain Res. Rev., 2000, 31(2/3), 288-294.
58. Hollmann, M.; Heinemann, S. Cloned glutamate receptors. Annu. Rev. Neurosci., 1994, 17, 31-108.
59. Wheal, H.V.; Thomson, A.M. Excitatory Amino Acids and Synaptic Transmission (2nd ed.). Academic Press: New York, 1995.
60. Malenka, R.C.; Nicoll, R.A. Long-term potentiation--a decade of progress? Science, 1999, 285(5435), 1870-1874.
61. Paoletti, P.; Neyton, J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol., 2007, 7(1), 39-47.
62. Sasaki, Y.F.; Rothe, T.; Premkumar, L.S.; Das, S.; Cui, J.; Talantova, M.V.; Wong, H.K.; Gong, X.; Chan, S.F.; Zhang, D.; Nakanishi, N.; Sucher, N.J.; Lipton, S.A. Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons. J. Neurophysiol., 2002, 87(4), 2052-2063.
63. Wee, K.S.; Zhang, Y.; Khanna, S.; Low, C.M. Immunolocalization of NMDA receptor subunit NR3B in selected structures in the rat forebrain, cerebellum, and lumbar spinal cord. J. Comp. Neurol., 2008, 509(1), 118-135.
64. Sun, L.; Shipley, M.T.; Lidow, M.S. Expression of NR1, NR2A-D, and NR3 subunits of the NMDA receptor in the cerebral cortex and olfactory bulb of adult rat. Synapse, 2000, 35(3), 212-221.
65. Greger, I.H.; Esteban, J.A. AMPA receptor biogenesis and trafficking. Curr. Opin. Neurobiol., 2007, 17(3), 289-297.
66. Greger, I.H.; Ziff, E.B.; Penn, A.C. Molecular determinants of AMPA receptor subunit assembly. Trends Neurosci., 2007, 30(8), 407-416.
67. Armstrong, N.; Sun, Y.; Chen, G.Q.; Gouaux, E. Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature, 1998, 395(6705), 913-917.
68. Rosenmund, C.; Stern-Bach, Y.; Stevens, C.F. The tetrameric structure of a glutamate receptor channel. Science, 1998, 280(5369), 1596-1599.
69. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S.F. The glutamate receptor ion channels. Pharmacol. Rev., 1999, 51(1), 7-61.
70. Lerma, J. Roles and rules of kainate receptors in synaptic transmission. Nat. Rev. Neurosci., 2003, 4(6), 481-495.
71. Huettner, J.E. Kainate receptors and synaptic transmission. Prog. Neurobiol., 2003, 70(5), 387-407.
72. Jaskolski, F.; Coussen, F.; Mulle, C. Subcellular localization and trafficking of kainate receptors. Trends Pharmacol. Sci., 2005, 26(1), 20-26.
73. Chittajallu, R.; Vignes, M.; Dev, K.K.; Barnes, J.M.; Collingridge, G.L.; Henley, J.M. Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature, 1996, 379(6560), 78-81.
74. Kerchner, G.A.; Wilding, T.J.; Huettner, J.E.; Zhuo, M. Kainate receptor subunits underlying presynaptic regulation of transmitter release in the dorsal horn. J. Neurosci., 2002, 22(18), 8010-8017.
75. Salt, T.E.; Eaton, S.A. Functions of ionotropic and metabotropic glutamate receptors in sensory transmission in the mammalian thalamus. Prog. Neurobiol., 1996, 48(1), 55-72.
76. Bellocchio, E.E.; Reimer, R.J.; Fremeau, R.T. Jr.; Edwards, R.H. Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science, 2000, 289(5481), 957-960.
77. Takamori, S.; Rhee, J.S.; Rosenmund, C.; Jahn, R. Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature, 2000, 407(6801), 189-194.
78. Lynch, M.A. Long-term potentiation and memory. Physiol. Rev., 2004, 84(1), 87-136.
79. Malinow, R. AMPA receptor trafficking and long-term potentiation. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2003, 358(1432), 707-714.
80. Lee, H.K., Takamiya, K.; Han, J.S.; Man, H.; Kim, C.H.; Rumbaugh, G.; Yu, S.; Ding, L.; He, C.; Petralia, R.S.; Wenthold, R.J.; Gallagher, M.; Huganir, R.L. Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory. Cell, 2003, 112(5), 631-643.
81. Lu, W.; Man, H.; Ju, W.; Trimble, W.S.; MacDonald, J.F.; Wang, Y.T. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron, 2001, 29(1), 243-254.
82. Hayashi, Y.; Shi, S.H.; Esteban, J.A.; Piccini, A.; Poncer, J.C.; Malinow, R. Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science, 2000, 287(5461), 2262-2267.
83. Nicoll, R.A.; Mellor, J.; Frerking, M.; Schmitz, D. Kainate receptors and synaptic plasticity. Nature, 2000, 406(6799), 957.
84. Schmitz, D.; Mellor, J.; Nicoll, R.A. Presynaptic kainate receptor mediation of frequency facilitation at hippocampal mossy fiber synapses. Science, 2001, 291(5510), 1972-1976.
85. Tu, J.C.; Xiao, B.; Naisbitt, S.; Yuan, J.P.; Petralia, R.S.; Brakeman, P.; Doan, A.; Aakalu, V.K.; Lanahan, A.A.; Sheng, M.; Worley, P.F. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron, 1999, 23(3), 583-592.
86. Naisbitt, S.; Kim, E.; Tu, J.C.; Xiao, B.; Sala, C.; Valtschanoff, J.; Weinberg, R.J.; Worley, P.F.; Sheng, M. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron, 1999, 23(3), 569-582.
87. Skeberdis, V.A.; Lan, J.; Opitz, T.; Zheng, X.; Bennett, M.V.; Zukin, R.S. MGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular calcium and activation of protein kinase C. Neuropharmacology, 2001, 40(7), 856-865.
88. Ambrosini, A.; Bresciani, L.; Fracchia, S.; Brunello, N.; Racagni, G. Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro. Mol. Pharmacol., 1995, 47(5), 1057-1064.
89. Lea, P.M.; Custer, S.J.; Vicini, S.; Faden, A.I. Neuronal and glial mGluR5 modulation prevents stretch-induced enhancement of NMDA receptor current. Pharmacol. Biochem. Behav., 2002, 73(2), 287-298.
90. Tsai, G.; Yang, P.; Chung, L.C.; Lange, N.; Coyle, J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry, 1998, 44(11), 1081-1089.
91. Heresco-Levy, U.; Javitt, D.C.; Ebstein, R.; Vass, A.; Lichtenberg, P.; Bar, G.; Catinari S.; Ermilov, M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatmentrefractory schizophrenia. Biol. Psychiatry, 2005, 57(6), 577-585.
92. Lane, H.Y.; Lin, C.H.; Huang, Y.J.; Liao, C.H.; Chang, Y.C.; Tsai, G.E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol., 2010, 13(4), 451-460.
93. Waziri, R. Glycine therapy of schizophrenia. Biol. Psychiatry, 1988, 23(2), 210-211.
94. Costa, J.; Khaled, E.; Sramek, J.; Bunney, W. Jr.; Potkin, S.G. An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J. Clin. Psychopharmacol., 1990, 10(1), 71-72.
95. Rosse, R.B.; Theut, S.K.; Banay-Schwartz, M.; Leighton, M.; Scarcella, E.; Cohen, C.G.; Deutsch, S.I. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an openlabel, pilot study. Clin. Neuropharmacol., 1989, 12(5), 416-424.
96. Javitt, D.C.; Zylberman, I.; Zukin, S.R.; Heresco-Levy, U.; Lindenmayer, J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry, 1994, 151(8), 1234-1236.
97. Heresco-Levy, U.; Javitt, D.C.; Ermilov, M.; Mordel, C.; Horowitz, A.; Kelly, D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry, 1996, 169(5), 610-617.
98. Heresco-Levy, U.; Javitt, D.C.; Ermilov, M.; Mordel, C.; Silipo, G.; Lichtenstein, M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry, 1999, 56(1), 29-36.
99. Heresco-Levy, U.; Javitt, D.C. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr. Res., 2004, 66(2-3), 89-96.
100. Leiderman, E.; Zylberman, I.; Zukin, S.R.; Cooper, T.B.; Javitt, D.C. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biol. Psychiatry, 1996, 39(3), 213-215.
101. Potkin, S.G.; Jin, Y.; Bunney, B.G.; Costa, J.; Gulasekaram, B. Effect of clozapine and adjunctive high-dose glycine in treatmentresistant schizophrenia. Am. J. Psychiatry, 1999, 156(1), 145-147.
102. Heresco-Levy, U.; Kremer, I.; Javitt, D.C.; Goichman, R.; Reshef, A.; Blanaru, M.; Cohen, T. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int. J. Neuropsychopharmacol., 2002, 5(4), 301-307.
103. Evins, A.E.; Amico, E.; Posever, T.A.; Toker, R.; Goff, D.C. DCycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr. Res., 2002, 56(1/2), 19-23.
104. Goff, D.C.; Tsai, G.; Levitt, J.; Amico, E.; Manoach, D.; Schoenfeld, D.A.; Hayden, D.L.; McCarley, R.; Coyle, J.T. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry, 1999, 56(1), 21-27.
105. Goff, D.C.; Tsai, G.; Manoach, D.S.; Coyle, J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry, 1995, 152(8), 1213-1215.
106. Buchanan R.W., Javitt, D.C., Marder, S.R., Schooler, N.R., Gold, J.M., McMahon, R.P., Heresco-Levy, U., Carpenter, W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry, 2007, 164(10), 1593-1602.
107. Goff, D.C.; Herz, L.; Posever, T.; Shih, V.; Tsai, G.; Henderson, D.C.; Freudenreich, O.; Evins, A.E.; Yovel, I.; Zhang, H.; Schoenfeld, D. A six-month; placebo-controlled trial of Dcycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl.), 2005, 179(1), 144-150.
108. Goff, D.C.; Tsai, G.; Manoach, D.S.; Flood, J.; Darby, D.G.; Coyle, J.T. D-cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiatry, 1996, 153(12), 1628-1630.
109. Tsai, G.E.; Yang, P.; Chang, Y.C.; Chong, M.Y. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry, 2006, 59(3), 230-234.
110. Rosse, R.B.; Schwartz, B.L.; Davis, R.E.; Deutsch, S.I. An NMDA intervention strategy in schizophrenia with low-dose milacemide. Clin. Neuropharmacol., 1991, 14(3), 268-272.
111. Rosse, R.B.; Schwartz, B.L.; Leighton, M.P.; Davis, R.E.; Deutsch, S.I. An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin. Neuropharmacol., 1990, 13(4), 348-354.
112. Javitt, D.C. Glycine transport inhibitors and the treatment of schizophrenia. Biol. Psychiatry, 2008, 63(1), 6-8.
113. Lane, H.Y.; Liu, Y.C.; Huang, C.L.; Chang, Y.C.; Liau, C.H.; Perng, C.H.; Tsai, G.E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol. Psychiatry, 2008, 63(1), 9-12.
114. Lane, H.Y.; Chang, Y.C.; Liu, Y.C.; Chiu, C.C.; Tsai, G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry, 2005, 62(11), 1196-1204.
115. Tsai, G.; Lane, H.Y.; Yang, P.; Chong, M.Y.; Lange, N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry, 2004, 55(5), 452-456.
116. Lane, H.Y.; Huang, C.L.; Wu, P.L.; Liu, Y.C.; Chang, Y.C.; Lin, P.Y.; Chen, P.W.; Tsai, G. Glycine transporter I inhibitor, Nmethylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry, 2006, 60(6), 645-649.
117. Wezenberg, E.; Verkes, R.J.; Ruigt, G.S.; Hulstijn, W.; Sabbe, B.G. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology, 2007, 32(6), 1272-1283.
118. Marenco, S.; Egan, M.F.; Goldberg, T.E.; Knable, M.B.; McClure, R.K.; Winterer, G.; Weinberger, D.R. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr. Res., 2002, 57(2-3), 221-226.
119. Goff, D.C.; Leahy, L.; Berman, I.; Posever, T.; Herz, L.; Leon, A.C.; Johnson, S.A.; Lynch, G. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J. Clin. Psychopharmacol., 2001, 21(5), 484-487.
120. Goff, D.C.; Lamberti, J.S.; Leon, A.C.; Green, M.F.; Miller, A.L.; Patel, J.; Manschreck, T.; Freudenreich, O.; Johnson, S.A. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology, 2008, 33(3), 465-472.
121. Tuominen, H.J.; Tiihonen, J.; Wahlbeck, K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res., 2005, 72(2/3), 225-234.
122. Tuominen, H.J.; Tiihonen, J.; Wahlbeck, K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst. Rev., 2006, (2), CD003730.
123. Kuo, C.C. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol. Pharmacol., 1998, 54(4), 712-721.
124. Large, C.H.; Webster, E.L.; Goff, D.C. The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl.), 2005, 181(3), 415-436.
125. Kremer, I.; Vass, A.; Gorelik, I.; Bar, G.; Blanaru, M.; Javitt, D.C.; Heresco-Levy, U. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol. Psychiatry, 2004, 56(6), 441-446.
126. Tiihonen, J.; Zamzow, C.R.; Robertson, H.; Dursun, S.M. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiatry, 2003, 54(11), 1241-1248.
127. Zoccali, R.; Muscatello, M.R.; Bruno, A.; Cambria, R.; Micò, U.; Spina, E.; Meduri, M. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr. Res., 2007, 93(1/3), 109-116.
128. Tiihonen, J.; Wahlbeck, K.; Kiviniemi, V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr. Res., 2009, 109(1/3), 10-14.
129. Premkumar, T.S.; Pick, J. Lamotrigine for schizophrenia. Cochrane Database Syst. Rev., 2006, (4), CD005962.
130. Glick, I.D.; Bosch, J.; Casey, D.E. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. J. Clin. Psychopharmacol., 2009, 29(3), 267-271.
131. Poyurovsky, M.; Glick, I.; Koran, L. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessivecompulsive symptoms. J. Psychopharmacol., 2010, 24(6), 861-866.
132. Goff, D.C.; Keefe, R.; Citrome, L.; Davy, K.; Krystal, J.H.; Large, C.; Thompson, T.R.; Volavka, J.; Webster, E.L. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J. Clin. Psychopharmacol., 2007, 27(6), 582-589.
133. Johnson, J.W.; Kotermanski, S.E. Mechanism of action of memantine. Curr. Opin. Pharmacol., 2006, 6(1), 61-67.
134. Krivoy, A.; Weizman, A.; Laor, L.; Hellinger, N.; Zemishlany, Z.; Fischel, T. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. Eur. Neuropsychopharmacol., 2008, 18(2), 117-121.
135. de Lucena, D.; Fernandes, B.S.; Berk, M.; Dodd, S.; Medeiros, D.W.; Pedrini, M.; Kunz, M.; Gomes, F.A.; Giglio, L.F.; Lobato, M.I.; Belmonte-de-Abreu, P.S.; Gama, C.S. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J. Clin. Psychiatry, 2009, 70(10), 1416-1423.
136. Gama, C.S.; Antunes, P.; Moser, C.; Belmonte-de-Abreu, P.S. Memantine as an adjunctive therapy for schizophrenia negative symptoms. Rev. Bras. Psiquiatr., 2005, 27(3), 257-258.
137. Lieberman, J.A.; Papadakis, K.; Csernansky, J.; Litman, R.; Volavka, J.; Jia, X.D.; Gage, A.; MEM-MD-29 Study Group. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology, 2009, 34(5), 1322-1329.
138. Thomas, C.; Carroll, B.T.; Maley, R.T.; Jayanti, K.; Koduri, A. Memantine and catatonic schizophrenia. Am. J. Psychiatry, 2005, 162(3), 626.
139. Carpenter, S.S.; Hatchett, A.D.; Fuller, M.A. Catatonic schizophrenia and the use of memantine. Ann. Pharmacother., 2006, 40(2), 344-346.
140. Carroll, B.T., Thomas, C.; Jayanti, K. Amantadine and memantine in catatonic schizophrenia. Ann. Clin. Psychiatry, 2006, 18(2), 133-134.
141. Naassila, M.; Hammoumi, S.; Legrand, E.; Durbin, P.; Daoust, M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol. Clin. Exp. Res., 1998, 22(4), 802-809.
142. Tek, C.; Srihari, V.; Tek, E. Successful acamprosate treatment of alcohol dependence in schizophrenia. Schizophr. Res., 2008, 106(2-3), 373.